A therapeutic dose of primaquine can be delivered across excised human skin from simple transdermal patches

International Journal of Pharmaceutics

Volumn 189, Issue 1, 1999, Pages 1-6

  Jeans, Christopher W ^a   Heard, Charles M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Acrylate adhesive; Malaria; Primaquine; Skin; Transdermal delivery

Indexed keywords

ADHESIVE AGENT; MIGLIOL 840; PENETRATION ENHANCING AGENT; PRIMAQUINE; STARCH; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALARIA CONTROL; NORMAL HUMAN; PRIORITY JOURNAL; SKIN PENETRATION; TRANSDERMAL DRUG ADMINISTRATION;

ADHESIVES; ADMINISTRATION, CUTANEOUS; ANTIMALARIALS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HALF-LIFE; HUMANS; MALE; PRIMAQUINE; SKIN ABSORPTION;

EID: 0032821253     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00215-X     Document Type: Article

References (16)

1. Baird J.K., Fryauff D.J., Basri H., Bangs M.J., Subianto B.B., Wiady I., Purnomo, Leksana B., Masbar S., Richie T.L., Jones T.R., Tjitra E., Wignall F.S., Hoffman S.L. Primaquine for prophylaxis against malaria among nonimmune transmigrants in irian-jaya, Indonesia. Am. J. Trop. Med. Hyg. 52(6):1995;479-484.
2. Benet L.Z., Kroetz D.L., Sheiner L.B. Pharmacokinetics: The dynamics of drug absorption, distribution and elimination. Hardman J.G., Goodman Gilman A., Limbird L.E. The Pharmacological Basis of Therapeutics. 9th edn:1996;McGraw-Hill, New York.
3. Clyde D.F. Clinical problems associated with the use of primaquine as a tissue schizonticidal and gametocytocidal drug. Bull. WHO. 59:1981;391-395.
4. Dua V.K., Kar P.K., Sarin R., Sharma V.P. High performance liquid chromatographic determination of primaquine and carboxyprimaquine concentrations in plasma and blood cells in Plasmodium vivax malaria following chronic dosage of primaquine. J. Chromatogr. B. 675:1996;93-98.
5. Fedors R. A method for estimating both the solubility parameters and molar volumes of liquids. Polym. Eng. Sci. 14:1974;147-154.
6. Fryauff D.J., Baird J.K., Basri H., Sumawinata I., Purnomo, Richie T.L., Ohrt C.K., Mouzin E., Church C.J., Richards A.L., Subianto B., Sandjaja B., Wignall F.S., Hoffman S.L. Randomized placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet. 346:1995;1190-1193.
7. Higuchi T. Physical chemical analysis of percutaneous absorption process from creams and ointments. J. Soc. Cosmet. Mater. 11:1960;85-97.
8. Jeans C., Allender C.J., Morris A., Brain K.R., Heard C.M. Release of primaquine from transdermal adhesive matrices. Brain K.R., Walters K.A. Perspectives in Percutaneous Penetration. 6a:1998;86 STS, Cardiff.
9. Liron Z., Cohen S. Percutaneous absorption of alkanoic acids 1: A study of operational conditions. J. Pharm. Sci. 73:1984;534-537.
10. Mayorga P., Puisieux F., Couarraze G. Formulation study of a transdermal delivery system of primaquine. Int. J. Pharm. 132:1996;71-79.
11. Mayorga P., Miltgen F., Coquelin F., Couarraze G. Rodent malaria prophylaxis by transdermal delivery of primaquine. Int. J. Parasitol. 28(8):1998;1283-1285.
12. Mihaly G.W., Ward S.A., Edwards G., L'E. Orme M., Breckenridge A.M. Pharmacokinetics of primaquine in man: I. Studies of the absolute bioavailability and dose size. Br. J. Clin. Pharmacol. 19:1985;745-750.
13. Mihaly G.W., Ward S.A., Edwards G., L'E. Orme M., Breckenridge A.M. Pharmacokinetics of primaquine in man: II. Comparison of acute vs. chronic dosage in Thai subjects. Br. J. Clin. Pharmacol. 19:1985;751-755.
14. Morris A., Kee W.J., Brain K.R., Heard C.M., Watkinson A.C. Vehicle effects in the permeation of primaquine across human skin in vitro. Brain K.R., James V.J., Walters K. Perspectives in Percutaneous Penetration. 5b:1998;180-182 STS, Cardiff.
15. Soto J., Toledo J., Rodriquez M., Sanchez J., Herrera R., Padilla J., Berman J. Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: Efficacy and toxicity. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 129:1998;241-244.
16. Thassu D., Vyas S.P. Controlled transdermal occlusive delivery device of primaquine. Drug Dev. Ind. Pharm. 19(11):1993;1343-1356.